Tin t&#x1EE9;c &amp; C&#x1EAD;p nh&#x1EAD;t

For patients with type 2 diabetes (T2D), the use of aspirin appears to lower the risk of incident pancreatic cancer, as shown in a retrospective cohort study.

Aspirin protects against pancreatic cancer in people with T2D

BP target in diabetics: How low should we go?

15 Jan 2025 bởi

Intensive blood-pressure (BP) lowering treatment targeted at a tighter systolic BP (SBP) yields cardiovascular benefits in Chinese patients with type 2 diabetes (T2D) and elevated BP in the randomized BPROAD* trial.

BP target in diabetics: How low should we go?

Potassium binder allows optimized MRA therapy in hyperkalaemic HFrEF patients

15 Jan 2025 bởi

Treatment with the potassium binder sodium zirconium cyclosilicate (SZC) stabilizes potassium levels in patients with heart failure with reduced ejection fraction (HFrEF) during spironolactone optimization, as shown in the prospective, randomized-withdrawal REALIZE-K trial.

Potassium binder allows optimized MRA therapy in hyperkalaemic HFrEF patients

Sequential oral meds fall short, insulin remains best for gestational diabetes

In the management of gestational diabetes, a sequential oral glucose-lowering medication strategy of metformin and additional glyburide, if needed, failed to demonstrate noninferiority to insulin, according to a study.

Sequential oral meds fall short, insulin remains best for gestational diabetes

Resilience tied to better mental health, QoL in bladder cancer

Baseline psychological resources (PR) are associated with improved mental health and quality-of-life (QoL) outcomes over time in patients with bladder cancer, suggest the results of a recent study.

Resilience tied to better mental health, QoL in bladder cancer

Ozanimod delivers real-world clinical benefits in ulcerative colitis

Treatment with ozanimod (oza) attains high efficacy rates in real-world clinical practice at week 12 for advanced therapy (AT)-naive patients with moderate-to-severe ulcerative colitis (UC) and at week 26 for those with AT exposure, as shown by initial results from POLARIS, an ongoing phase IV open-label study.

Ozanimod delivers real-world clinical benefits in ulcerative colitis

Testosterone does not induce recurrence in men after RP

Select men who underwent radical prostatectomy (RP) for organ-confined prostate cancer may safely use testosterone therapy, which does not seem to cause biochemical recurrence (BCR), according to a study.

Testosterone does not induce recurrence in men after RP

Acalabrutinib-venetoclax hits mark for fit TN CLL patients

The interim analysis of the AMPLIFY trial provides the first phase III evidence of fixed-duration therapy combining a second-generation Bruton tyrosine kinase inhibitor (BTKi) with venetoclax with or without anti-CD20 for treatment-naïve (TN) chronic lymphocytic leukaemia (CLL).

Acalabrutinib-venetoclax hits mark for fit TN CLL patients

14 Jan 2025

Higher daily steps may alleviate depression in adults

Higher daily step count is associated with fewer depressive symptoms in the general adult population, according to the results of a systematic review and meta-analysis.

Higher daily steps may alleviate depression in adults

Pirtobrutinib scores a phase III win in BTKi-pretreated CLL/SLL